David Berl, a partner and Co-Chair of Patent Litigation at Williams & Connolly, continues to make waves in the legal field with his notable work, including his successful representation of Regeneron Pharmaceuticals Inc. in a high-stakes patent case. The Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals, Inc. case stands out as a significant feat, underscoring Berl’s adept trial strategy and deep understanding of the Biologics Price Competition and Innovation Act (BPCIA).
Berl’s approach in the Regeneron case was characterized by a strategic narrowing of focus early on and accelerating the trial timeline. This deviation from conventional litigation processes allowed for an expedited resolution, crucial in a field where innovator companies often face challenges under the BPCIA framework. Berl capitalized on inconsistencies in the defense’s case, leveraging expert testimonies to paint a coherent and compelling narrative to the court, thus affirming the strength and validity of Regeneron’s patent.
Despite facing a major hurdle with an adverse pre-trial ruling on patent claims, Berl and his team turned the setback into an opportunity. By advancing alternative arguments and maintaining a focus on complex technical details, Berl was able to navigate the complexities successfully, reinforcing the value and robustness of Regeneron’s legal position.
Reflecting on his choice to pursue a career in trial law, Berl attributes his decision to a lifelong passion for competition, likening trials to “sports for unathletic people.” He emphasizes the importance of storytelling in trials and advises young lawyers to take calculated risks, reminding them that not all poor outcomes are the result of poor decisions—a lesson gleaned from his extensive experience in the courtroom.
As legal professionals continue to follow notable figures in the industry, Berl’s experience and strategic acumen serve as a testament to the enduring importance of adaptability and precision in trial advocacy, particularly in the nuanced arena of patent litigation. For more on Berl’s legal career and insights into his successful strategies, visit Bloomberg Law’s full coverage.